Prostate-specific membrane antigen positron-emission tomography for novel risk-stratification of biochemical recurrence.

IF 2.1 3区医学 Q2 UROLOGY & NEPHROLOGY

Current Opinion in Urology Pub Date : 2025-04-23 DOI:10.1097/MOU.0000000000001291

Madeleine J Karpinski, Claudia Kesch, Boris A Hadaschik, Wolfgang P Fendler

{"title":"Prostate-specific membrane antigen positron-emission tomography for novel risk-stratification of biochemical recurrence.","authors":"Madeleine J Karpinski, Claudia Kesch, Boris A Hadaschik, Wolfgang P Fendler","doi":"10.1097/MOU.0000000000001291","DOIUrl":null,"url":null,"abstract":"Purpose of review: The variety of prostate cancer aggressiveness in patients with biochemical recurrence (BCR) leads to the unmet need of accurate risk stratification. This review examined the recently published risk stratification tool using prostate-specific membrane antigen positron-emission tomography (PSMA-PET) compared to the risk categories by European Association of Urology (EAU).Recent findings: The risk stratification by EAU was proposed for patients with BCR, including the doubling time of the prostate-specific-antigen and Gleason score as predictors for survival. Although stratification into low- vs. high-risk groups reached significant differences in the external validation, C-indices determined moderate discriminative ability and the need to improve the EAU risk categories. PSMA-PET was recently validated as prognostic biomarker and PSMA-PET standardized by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) metrics were combined to create a visual and a quantitative nomogram to predict overall survival.Summary: The unmet need to improve risk stratification for prostate cancer patients experiencing BCR was addressed with PSMA-PET PROMISE (PPP) nomograms. Although PPP nomograms are not applied for individual patient counselling yet, they can be used additionally to EAU risk categories.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOU.0000000000001291","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The variety of prostate cancer aggressiveness in patients with biochemical recurrence (BCR) leads to the unmet need of accurate risk stratification. This review examined the recently published risk stratification tool using prostate-specific membrane antigen positron-emission tomography (PSMA-PET) compared to the risk categories by European Association of Urology (EAU).

Recent findings: The risk stratification by EAU was proposed for patients with BCR, including the doubling time of the prostate-specific-antigen and Gleason score as predictors for survival. Although stratification into low- vs. high-risk groups reached significant differences in the external validation, C-indices determined moderate discriminative ability and the need to improve the EAU risk categories. PSMA-PET was recently validated as prognostic biomarker and PSMA-PET standardized by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) metrics were combined to create a visual and a quantitative nomogram to predict overall survival.

Summary: The unmet need to improve risk stratification for prostate cancer patients experiencing BCR was addressed with PSMA-PET PROMISE (PPP) nomograms. Although PPP nomograms are not applied for individual patient counselling yet, they can be used additionally to EAU risk categories.

查看原文本刊更多论文

前列腺特异性膜抗原正电子发射断层扫描用于生化复发的新型风险分层。

回顾目的：前列腺癌生化复发（BCR）患者侵袭性的多样性导致准确的风险分层的需求未得到满足。本综述对最近发表的前列腺特异性膜抗原正电子发射断层扫描（PSMA-PET）的风险分层工具与欧洲泌尿外科协会（EAU）的风险分类进行了比较。最近发现：对BCR患者提出了EAU风险分层，包括前列腺特异性抗原加倍时间和Gleason评分作为生存的预测指标。尽管在外部验证中将低风险组与高风险组分层存在显著差异，但c指数确定了中度判别能力和改善EAU风险类别的必要性。PSMA-PET最近被证实为预后生物标志物，PSMA-PET通过前列腺癌分子成像标准化评估（PROMISE）指标标准化，结合创建视觉和定量nomogram来预测总生存期。摘要：PSMA-PET PROMISE (PPP) x线图解决了前列腺癌BCR患者改善风险分层的未满足需求。虽然PPP线图尚未应用于个别患者咨询，但它们可以额外用于EAU风险类别。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Urology 医学-泌尿学与肾脏学

CiteScore

5.00

自引率

4.00%

发文量

140

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Urology delivers a broad-based perspective on the most recent and most exciting developments in urology from across the world. Published bimonthly and featuring ten key topics – including focuses on prostate cancer, bladder cancer and minimally invasive urology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.